Your browser doesn't support javascript.
loading
[Some HBeAg-negative chronic hepatitis B patients treated with nucleos(t)ide analogue can achieve HBsAg loss after drug withdrawal: stop-to-cure may be coming].
Lu, F M; Yu, Y C; Gao, L; Jiang, Q Q; Chen, X M; Zhuang, Hui.
Affiliation
  • Lu FM; Peking University Hepatology Institute, Peking University People's Hospital, Beijing 100044, China.
  • Yu YC; Department of Infectious Diseases and Center of Liver Diseases, General Hospital of Eastern Theater Command, Nanjing 210002, China.
  • Gao L; Department of Infectious Disease and Hepatology, the Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250033, China.
  • Jiang QQ; Peking University Hepatology Institute, Peking University People's Hospital, Beijing 100044, China.
  • Chen XM; Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
  • Zhuang H; Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
Zhonghua Yi Xue Za Zhi ; 102(40): 3160-3166, 2022 Nov 01.
Article in Zh | MEDLINE | ID: mdl-36319170

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hepatitis B, Chronic / Hepatitis B Surface Antigens Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: Zh Journal: Zhonghua Yi Xue Za Zhi Year: 2022 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hepatitis B, Chronic / Hepatitis B Surface Antigens Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: Zh Journal: Zhonghua Yi Xue Za Zhi Year: 2022 Document type: Article Affiliation country: Country of publication: